IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies
Integrated BioTherapeutics, Inc. (IBT), a leader in infectious disease and filovirus research, today announced the discovery of novel Pan-Ebola and Pan-Filovirus monoclonal antibodies (mAbs). IBT scientists presented the new mAbs at the 7th International Symposium on Filoviruses held in Washington, DC.
IBT’s broad-spectrum filovirus mAbs and cocktails are planned for development as therapeutics against filoviruses Ebola (EBOV), Sudan (SUDV), Bundibugyo (BUDV), Reston (RESTV), and Marburg (MARV). Filoviruses are highly pathogenic, high-priority public health threats with no approved vaccines or therapeutics. Current monoclonal antibody and vaccine candidates are mostly strain-specific and primarily target EBOV Zaire. Filoviruses are endemic in Africa and have caused periodic outbreaks, including the ongoing international EBOV epidemic, and are also potential bioweapon and bioterrorist threats. Patients develop severe hemorrhagic disease with up to 90% mortality. There is thus a strong unmet public health and biodefense need for broad-spectrum treatments for these highly pathogenic viruses.
The broad-spectrum filovirus mAb candidates were discovered by immunizing mice and Rhesus macaques with IBT’s proprietary filovirus antigens, isolating and cloning B cells from the animals, screening mAbs for binding to filoviruses, and conducting affinity maturation. Development then proceeded to expressing test mAb lots as humanized chimeric monoclonal IgGs, followed by characterization and efficacy testing in mouse models.
Our novel mAb candidates and cocktails have shown intriguing protection in mice against a broad spectrum of filoviruses. Cocktails of these mAbs have shown complete protection against multiple filoviruses. Our broad-spectrum filovirus mAbs bind to novel pan-Ebola and pan-filovirus epitopes. The epitopes are conserved across multiple filoviruses, enabling broad-spectrum activity and suggesting emergence of viral resistance may be limited.
The antibodies could be deployed against filoviruses in the same way that monoclonal antibody treatment or collected serum from survivors have been used in the ongoing Ebola outbreak originating in West Africa. Our mAbs or cocktails could also be considered as a prophylactic in endemic areas, before travelling, or for caregivers in close contact with filovirus patients.
Our mAbs are at the lead selection stage. The next steps in development are to select one or more broad-spectrum mAbs or cocktails as preferred lead candidates, complete proof of concept studies in rodents and NHPs, and commence a program directed towards IND and Phase 1 clinical trials.
IBT's broad-spectrum filovirus mAbs have the following key advantages:
- Potential for mAb or mAb cocktail to treat multiple filovirus diseases
- Novel target epitopes conserved across multiple filoviruses enable broad-spectrum activity and suggest emergence of viral resistance may be limited
- Ready for lead selection